| Literature DB >> 28566814 |
M T Lane1, T J Herda2, A C Fry2, M A Cooper2, M J Andre3, P M Gallagher2.
Abstract
Leucine ingestion reportedly activates the mTOR pathway in skeletal muscle, contributing to a hypertrophy response. The purpose of the study was to compare the post-resistance exercise effects of leucine and whey protein supplementation on endocrine responses and muscle mTOR pathway phosphorylation. On visit 1, subjects (X±SD; n=20; age=27.8±2.8yrs) provided baseline blood samples for analysis of cortisol, glucose and insulin; a muscle biopsy of the vastus lateralis muscle to assess mTOR signaling pathway phosphorylation; and were tested for maximum strength on the leg press and leg extension exercises. For visits 2 and 3, subjects were randomized in a double-blind crossover design to ingest either leucine and whey protein (10g+10g; supplement) or a non-caloric placebo. During these visits, 5 sets of 10 repetitions were performed on both exercises, immediately followed by ingestion of the supplement or placebo. Blood was sampled 30 min post-, and a muscle biopsy 45 min post-exercise. Western blots quantified total and phosphorylated proteins. Insulin increased (α<.05) with supplementation with no change in glucose compared to placebo. Relative phosphorylation of AKT and rpS6 were greater with leucine and whey supplementation compared to placebo. Supplementation of leucine and whey protein immediately after heavy resistance exercise increases anabolic signaling in human skeletal muscle.Entities:
Keywords: AKT; Hypertrophy; Leucine; Resistance training; mTOR
Year: 2017 PMID: 28566814 PMCID: PMC5424460 DOI: 10.5114/biolsport.2017.65339
Source DB: PubMed Journal: Biol Sport ISSN: 0860-021X Impact factor: 2.806
Fig. 1Akt phosphorylated to total protein ratio normalized values to baseline session values (X±SD). There were significantly greater levels of phosphorylation for the supplement condition over both the placebo (+) and baseline visit (*) (p<.05).
Fig. 5rpS6 phosphorylated to total protein ratio normalized values to baseline session values (X±SD). Both the supplement and placebo conditions were significantly greater than the baseline session (*) (p<.05). The supplement session was significantly greater than the placebo condition (+) (p<.05).
Concentrations for each blood variable (X±SD).
| Baseline | Supplement | Placebo | |
|---|---|---|---|
| Insulin ( | 15.4±17.3 | 85.6±69.9 | 22.5±29.2 |
| Cortisol (nmol×L-1) | 471.7±176.0 | 495.8±221.7 | 517.3±201.7 |
| Glucose (mg×dL-1) | 2.6±1.0 | 2.6±0.7 | 2.9±0.7 |
p<.05, different than baseline and placebo
Fig. 3p70s6k phosphorylated to total protein ratio normalized values to baseline session values (X±SD). Both the supplement and placebo conditions were significantly greater than the baseline session (*) (p<.05).
Fig. 2mTOR phosphorylated to total protein ratio normalized values to baseline session values (X±SD). There was no significant change in levels of phosphorylation between any visit (p>.05).
Fig. 44E-BP1 phosphorylated to total protein ratio normalized values to baseline session values (X±SD). There was no significant change in levels of phosphorylation between any visit (p>.05).
Significant changes in protein phosphorylation relative to baseline or placebo conditions.
| Supplement | Placebo | |
|---|---|---|
| Insulin | ↑↑ | ↔ |
| AKT | ↑ | ↔ |
| mTOR | ↔ | ↔ |
| 4E-BP1 | ↔ | ↔ |
| P70s6k | ↑ | ↑ |
| rpS6 | ↑↑ | ↑ |
↑ = significant change relative to baseline
↑↑ = significant change relative to baseline and placebo
↔ = no change relative to baseline